Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma

Tumori

Volumn 99, Issue 4, 2013, Pages 480-487

  Yoon, Sang Min ^a   Kim, Jeong Hoon ^a   Kim, Sang Joon ^a   Khang, Shin Kwang ^a   Shin, Seong Soo ^a   Cho, Young Hyun ^a   Jwa, Eunjin ^a   Park, Jin Hong ^a   Ahn, Seung Do ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Glioblastoma; Intensity modulated radiotherapy; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BRAIN TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONCURRENT CHEMORADIOTHERAPY; CRANIOTOMY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LIVER TOXICITY; MALE; MOTOR DYSFUNCTION; NAUSEA; RADIATION DOSE; RADIATION NECROSIS; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NECROSIS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84890863069     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1361.15098     Document Type: Article

References (20)

1. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM: Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol, 20: 1635-1642, 2002.
2. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, Malkin MG, Mealey JJ, Jr, Neal JH, Olson J, Robertson JT, Barnett GH, Bloomfield S, Albright R, Hochberg FH, Hiesiger E, Green S: The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery, 51: 343-357, 2002.
3. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys, 60: 853-860, 2004.
4. Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, Nelson JS, Weinstein AS, Curran WJ, Jr: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer, 77: 1535-1543, 1996.
5. Budach W, Gioioso D, Taghian A, Stuschke M, Suit HD: Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys, 39: 743-750, 1997.
6. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G: Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys, 73: 473-478, 2009.
7. Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, Gildenberg PL, Holoye P, Augspurger ME, Carpenter LS, Lu HH, Chiu JK, Grant WH, 3rd, Butler EB: Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 58: 721-726, 2004.
8. Iuchi T, Hatano K, Narita Y, Kodama T, Yamaki T, Osato K: Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys, 64: 1317-1324, 2006.
9. Nakamatsu K, Suzuki M, Nishimura Y, Kanamori S, Koike R, Shibata T, Shintani N, Okumura M, Okajima K, Akai F: Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy. Int J Clin Oncol, 13: 48-53, 2008.
10. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA: Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys, 64: 892-897, 2006.
11. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10: 459-466, 2009.
12. Curran WJ, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 85: 704-710, 1993.
13. Hulshof MC, Schimmel EC, Andries Bosch D, Gonzalez Gonzalez D: Hypofractionation in glioblastoma multiforme. Radiother Oncol, 54: 143-148, 2000.
14. Laperriere N, Zuraw L, Cairncross G: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol, 64: 259-273, 2002.
15. Buatti J, Ryken TC, Smith MC, Sneed P, Suh JH, Mehta M, Olson JJ: Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol, 89: 313-337, 2008.
16. Cho KH, Kim JY, Lee SH, Yoo H, Shin SH, Moon SH, Kim TH, Shin KH, Yoon M, Lee DH, Pyo HR: Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys, 78: 390-397, 2010.
17. Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M, Calista F, Digesu C, Macchia G, Ianiri M, Deodato F, Cilla S, Piermattei A, Valentini V, Cellini N, Cantore GP: A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys, 77: 92-97, 2010.
18. Gutin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, Sneed PK, Levin VA, Weaver KA, Silver P, Lamborn K, Lamb S, Ham B: External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys, 21: 601-606, 1991.
19. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 7: 392-401, 2006.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352: 997-1003, 2005.